ACPH Acacia Pharma Group PLC

Issue of Equity on Exercise of Options/Vesting of Performance Share Awards

Issue of Equity on Exercise of Options/Vesting of Performance Share Awards



Cambridge, UK and Indianapolis, US – 9 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that application has been made to Euronext Brussels for the admission of 237,000 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.

Following issue of the New Ordinary Shares, the Company's total issued share capital consists of 64,119,865 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 64,119,865.

Contacts

Acacia Pharma Group plc

Mike Bolinder, CEO

Gary Gemignani, CFO

/

 

Citigate Dewe Rogerson (Financial PR)

Mark Swallow, Frazer Hall, David Dible

1

EN
09/03/2020

Underlying

ACPHAcacia Pharma Group PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acacia Pharma Group PLC

 PRESS RELEASE
Free
ACPH Acacia Pharma G...

Scheme of arrangement becoming effective

Scheme of arrangement becoming effective Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Scheme becomi...

June 9, 2022 1 EN
 PRESS RELEASE
Free
ACPH Acacia Pharma G...

Court Sanction of the Scheme of Arrangement

Court Sanction of the Scheme of Arrangement Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, [1.00] p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under ...

June 7, 2022 1 EN
 PRESS RELEASE
Free
ACPH Acacia Pharma G...

Acacia Pharma Results of the Court Meeting and the General Meeting hel...

Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected b...

May 20, 2022 1 EN
 PRESS RELEASE
Free
ACPH Acacia Pharma G...

Publication of Annual Report and Financial Statements for the Year end...

Publication of Annual Report and Financial Statements for the Year ended 31 December 2021 This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer ...

April 29, 2022 1 EN
 PRESS RELEASE
Free
ACPH Acacia Pharma G...

Publication of Scheme Document

Publication of Scheme Document Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 27 April 2022, 12:00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Publication of Schem...

April 27, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch